Inspira Technologies Oxy B.H.N. Ltd. (NASDAQ:IINN) Sees Large Drop in Short Interest

Inspira Technologies Oxy B.H.N. Ltd. (NASDAQ:IINN) was the target of a significant decline in short interest during the month of February. As of February 28th, there was short interest totalling 147,400 shares, a decline of 71.7% from the February 13th total of 520,300 shares. Currently, 0.7% of the company’s stock are sold short. Based on an average trading volume of 1,130,000 shares, the days-to-cover ratio is presently 0.1 days.

Inspira Technologies Oxy B.H.N. Price Performance

Shares of IINN traded up $0.03 during trading on Friday, reaching $0.73. The company’s stock had a trading volume of 138,260 shares, compared to its average volume of 1,421,372. The company has a debt-to-equity ratio of 0.09, a quick ratio of 2.13 and a current ratio of 2.23. The company has a fifty day moving average of $0.92 and a two-hundred day moving average of $1.13. Inspira Technologies Oxy B.H.N. has a twelve month low of $0.65 and a twelve month high of $2.45.

Institutional Trading of Inspira Technologies Oxy B.H.N.

A hedge fund recently raised its stake in Inspira Technologies Oxy B.H.N. stock. Citadel Advisors LLC raised its position in shares of Inspira Technologies Oxy B.H.N. Ltd. (NASDAQ:IINN) by 422.5% during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 86,763 shares of the company’s stock after buying an additional 70,159 shares during the quarter. Citadel Advisors LLC owned about 0.69% of Inspira Technologies Oxy B.H.N. worth $88,000 at the end of the most recent quarter. Institutional investors and hedge funds own 12.72% of the company’s stock.

Inspira Technologies Oxy B.H.N. Company Profile

Inspira Technologies Oxy B.H.N. Ltd., a specialty medical device company, engages in the research, development, manufacture, and marketing of respiratory support technology to provide an alternative to invasive mechanical ventilation for the treatment of acute respiratory failure. Its lead product is the augmented respiration technology system, a respiratory support system comprising minimally invasive, portable dual lumen cannula, which is inserted into the jugular vein and utilizes extra-corporeal direct blood oxygenation to elevate and stabilize declining oxygen saturation levels.